Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia

Published:2013-04 Issue:4 Volume:37 Page:440-446
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Laprevotte Emilie,Ysebaert Loïc,Klein Christian,Valleron Wilfried,Blanc Amandine,Gross Emilie,Laurent Guy,Fournié Jean-Jacques,Quillet-Mary Anne

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference48 articles.

1. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia;Tam;Blood,2008

2. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

3. Mechanisms of killing by anti-CD20 monoclonal antibodies;Glennie;Mol Immunol,2007

4. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains;Bezombes;Blood,2004

5. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms;Harjunpaa;Scand J Immunol,2000

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling;PLOS Medicine;2024-07-22

2. The dual role of complement in cancers, from destroying tumors to promoting tumor development;Cytokine;2021-07

3. Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse;Biomarker Research;2020-12

4. Recent Advances in the Use of NK Cells Against Cancer;Cancer Immunology;2020-09-25

5. A tale of two antibodies: obinutuzumabversusrituximab;British Journal of Haematology;2018-05-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3